VALIDATED AND QUANTIFIED STABILITY INDICATING STRESS DEGRADATION STUDY OF ORAL ANTI-DIABETIC AGENT CANAGLIFLOZIN BY RP-HPLC METHOD
Keywords:Canagliflozin, Stress degradation, Validation, ICH, Forced stability, SGLT2, RP-HPLC
Objective: The present investigation is aimed to develop and validate, a simple, consistent and sensitive stability-indicating reverse phase-high performance liquid chromatography (RP-HPLC) method for the determination of oral anti-diabetic drug Canagliflozin in bulk and pharmaceutical dosage form as per the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH-Q2 (R1)).
Methods: The chromatographic separation was achieved by using Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) ZORBAX C18 (250 mm x 4.6 mm, 5μm particle size) with a mobile phase consisting of Acetonitrile: Water in a ratio of 53:47% v/v at a flow rate of 1 ml/min with an injection volume of 20 μl.
Results: The Retention time of the drug Canagliflozin was found to be 2.36±0.05 min and detected at 214 nm UV wavelength. The linear regression equation was found to be y = 60702x–2156.2 with a correlation coefficient 0.9999. Stress degradation studies were performed by exposing the Canagliflozin into acidic, alkaline, oxidative, thermal and photolytic stress conditions with active samples withdrawn at different time intervals as per ICH guidelines.
Conclusion: The proposed Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) method was found to be robust, precise and specific for estimation of Canagliflozin in pharmaceutical dosage forms.
Harsharan PS, Ishpreet K, Gunjan S. Sodium-glucose co-transporters-2 (SGLT2) inhibitors as a new class of anti-diabetic drugs: pharmacokinetics, efficacy and clinical significance. Int J Pharm Sci Rev Res 2015;33:40-7.
Wright EM, Turk E. The sodium/glucose co-transport family SLC5. Pflugers Arch 2004;447:510-8.
Nair S, Wilding JP. Sodium-glucose co-transporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95:34-42.
Misra M. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. J Pharm Pharmacol 2013;65:317-27.
Strojek K, Yoon KH, Hruba V. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obesity Metab 2011;13:928-38.
Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metabolism Syndrome Obesity 2012;5:313-27.
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/204042Orig1s032TOC.cfm [Last accessed on 02 Jan 2021]
Muzaffar I, Nasr YK, Amer MA, Khalid A Al-R. A simple and sensitive high-performance liquid chromatography assay with a fluorescence detector for determination of canagliflozin in human plasma. Anal Methods 2015;7:3028-35.
Suneetha, D Sharmila. A validated stability indicating RP-HPLC method for estimation of canagliflozin in dosage form. Res J Pharm Biol Chem Sci 2015;6:1186-94.
Ishpreet K, Sharad W, Harsharan PS, Satish M. Development and validation of a stability-indicating reverse phase HPLC-PDA method for determination of canagliflozin in bulk and pharmaceutical dosage form. Pharm Methods 2016;7:54-62.
Sonia D, Muddu K, Gude SS, Vasantharaju SG. Stability indicating assay method development and validation to simultaneously estimate metformin hydrochloride and canagliflozin by RP-HPLC. Curr Trends Biotechnol Pharm 2016;10:334-42.
Deepak G, Patil RN, Mangesh H. A validated stability-indicating RP-HPLC method for simultaneous determination of metformin and canagliflozin in pharmaceutical formulation. World J Pharm Pharm Sci 2015;4:631-40.
Uttam PP, Sunil KR. A novel validated RP-HPLC-DAD method for the simultaneous estimation of metformin hydrochloride and canagliflozin in bulk and pharmaceutical tablet dosage form with forced degradation studies. Orient J Chem 2015;31:1489-507.
Nareddy PR, Naga TC. RP-HPLC method development and validation for the simultaneous estimation of metformin and canagliflozin in tablet dosage form. Int J Pharm Sci 2015;5:1155-9.
Muzaffar I, Nasr YK, Amer MA, Khalid A. A simple and sensitive high performance liquid chromatography assay with a fluorescence detector for determination of canagliflozin in human plasma. Anal Methods 2015;7:3028-35.
Ishpreet K, Sharad W, Harsharan PS. Development and validation of a stability-indicating high-performance thin-layer chromatography (HPTLC) method for estimation of canagliflozin in bulk and pharmaceutical dosage form. J Appl Pharm Sci 2016;6:51-7.
Ishpreet K, Sharad W, Harsharan PS, Satish M. Development and validation of UV spectroscopic method for determination of canagliflozin in bulk and pharmaceutical dosage form. Pharmaceutical Methods 2015;6:82-6.
Nirali DP, Darshil BS, Dilip GM. Development and validation of UV spectrophotometric estimation of canagliflozin in its pharmaceutical dosage form. Int J Pharm Technol 2015;7:9779-84.
Iqbal M, Ezzeldin E, Al-Rashood KA. Rapid determination of canagliflozin in rat plasma by UHPLC–MS/MS using negative ionization mode to avoid adduct-ions formation. Talanta 2015;132:29-36.
Dudhe PB, Kamble MC. RP-HPLC method development and validation for the determination of canagliflozin in human plasma. Int J Pharm Res Technol 2016;9:174-81.
Kobuchi S, Yano K, Ito Y, Sakaeda T. A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. Biomed Chromatography 2016;30:1549-55.
ICH guideline Q1A (R2). Stability testing of new drug substances and products. ICH; 2003. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf [Last accessed on 02 Jan 2021]
ICH guideline Q2 (R1). Validation of analytical procedures: text and methodology. ICH. 2005. Available from: http://www.ich.org/ fileadmin/Public_Web_Site/ICH_ Products/Guidelines/Quality/ Q2_R1/Step4/Q2_R1__Guideline.pdf [Last accessed on 02 Jan 2021].
How to Cite
Copyright (c) 2021 ARULSELVAN MURUGESAN, MUKTHINUTHALAPATI MATHRUSRI ANNAPURNA
This work is licensed under a Creative Commons Attribution 4.0 International License.